EPO Specific Neutra™ Antibody Products

Product list

Accelerate Your Research and Development!

Are you currently facing challenges in autoimmune disease diagnostics, biomarker discovery, or the development of highly specific research tools? At Creative Biolabs, our EPO Specific Antibody Products offer unparalleled precision and reliability, providing critical solutions for your most demanding projects in autoimmune research and diagnostics. We deliver highly characterized antibodies and comprehensive support to ensure your success.

Contact our team to get an inquiry now!

Introduction of EPO

Erythropoietin (EPO), a vital glycoprotein hormone produced mainly by renal tissues during cellular hypoxia (low oxygen conditions), is central to erythropoiesis – red blood cell generation in bone marrow. Its core structure comprises 165 amino acids and undergoes significant glycosylation, critical for biological functionality and molecular stability.

EPO's primary function is to stimulate the proliferation, differentiation, and survival of erythroid progenitor cells in the bone marrow. This action leads to an increased production of red blood cells, which are vital for oxygen delivery to tissues and the transport of carbon dioxide away from them. The binding of EPO to its specific receptor (EPOR) on target cells initiates a complex cascade of intracellular signaling pathways, primarily involving the JAK2/STAT5 pathway, but also engaging PI3K/Akt and MAPK pathways. These pathways collectively promote cell survival, inhibit apoptosis, and drive the maturation of red blood cell precursors.

Fig 1. Schematic of effects of erythropoietin. (OA Literature) Fig. 1 Pleiotropic effects of erythropoietin¹

Abnormalities in EPO regulation or signaling pathways underlie multiple pathologies. Insufficient EPO concentrations serve as a diagnostic indicator of anemia, frequently observed in chronic kidney disease (CKD) patients linked to compromised kidney-derived EPO synthesis and individuals receiving cancer treatment regimens. Excessively elevated EPO concentrations may induce polycythemia, marked by erythrocyte overproduction that elevates blood viscosity and thrombosis risks. A critical yet uncommon complication of recombinant EPO administration involves antibody-mediated pure red cell aplasia (PRCA), where neutralizing anti-EPO antibodies precipitate profound anemia. Comprehending these complex biological mechanisms remains pivotal for advancing translational research and optimizing clinical interventions.

Antibodies Against EPO

Antibodies targeting Erythropoietin (EPO) are indispensable tools across diverse research, diagnostic, and biopharmaceutical applications, specifically designed to recognize and bind EPO for its detection, quantification, and functional modulation.

The applications of anti-EPO antibodies are varied:

Research Applications:
- Western Blot (WB): Detects and quantifies EPO protein expression in biological samples, aiding insights into EPO production and regulation.
- Immunohistochemistry (IHC) and Immunofluorescence (IF): Localizes EPO within tissues and cells, identifying EPO-producing cells and studying distribution.
- Flow Cytometry: Enables EPO detection on cell surfaces or intracellularly, useful for studying EPOR expression and signaling.
- ELISA (Enzyme-Linked Immunosorbent Assay): A widely used quantitative method for measuring EPO levels in biological fluids, crucial for studying EPO kinetics and disease roles.
Diagnostic Applications:
- EPO Level Measurement: These antibodies are the cornerstone for diagnostic assays (primarily ELISA) to measure circulating EPO levels, aiding in diagnosing anemia causes (e.g., EPO-deficient) and polycythemia.
- Detection of Anti-EPO Antibodies: Crucial for identifying neutralizing anti-EPO antibodies in patients on recombinant EPO therapy, vital for diagnosing and managing antibody-associated pure red cell aplasia (PRCA).
Drug Development and Biopharmaceutical Applications:
- Therapeutic Monitoring: Monitors therapeutic recombinant EPO levels in patients for optimal dosing and efficacy.
- Immunogenicity Assessment: Essential for evaluating potential immune responses against therapeutic proteins during biosimilar or novel EPO mimetic development.
- Pharmacokinetic/Pharmacodynamic (PK/PD) Studies: Facilitates studies on therapeutic EPO's absorption, distribution, metabolism, excretion, and its physiological effects.

Creative Biolabs’ EPO Specific Antibody Products are developed for these critical applications, ensuring high performance, reliability, and consistency.

Why Choose Us?

Choosing Creative Biolabs for your EPO Specific Antibody Products means partnering with a leader dedicated to scientific excellence and client success. Our commitment to quality, innovation, and support sets us apart.

Unrivaled Specificity and Affinity: Our antibodies are engineered and rigorously screened to ensure high specificity for EPO, minimizing off-target binding and delivering clean, interpretable results.
Extensive Application Validation: Each antibody is thoroughly validated across multiple key applications (e.g., Western Blot, IHC, ELISA, Flow Cytometry), providing confidence in its performance for your experimental needs.
Consistent Batch-to-Batch Quality: We implement stringent quality control measures throughout our production process, guaranteeing minimal batch-to-batch variation and ensuring reproducibility in your long-term studies.
Expert Technical Support: Our team of experienced scientists is available to provide comprehensive technical assistance, from experimental design to troubleshooting, ensuring you maximize the utility of our products.
Rapid Turnaround Times: We understand the urgency of research. Our optimized workflows enable efficient antibody development and delivery without compromising on quality.

FAQs

Here are some common questions from researchers and clinicians interested in EPO Specific Antibody Products:

Q: What are the key considerations for ensuring the high specificity of anti-Erythropoietin antibodies in experimental assays?

A: At Creative Biolabs, our EPO antibodies undergo a rigorous development and validation process. We employ advanced antigen design, robust immunization strategies, and multi-stage screening protocols to select clones with exceptional specificity. Furthermore, each antibody is extensively validated across multiple applications to confirm its specific binding to EPO and minimal cross-reactivity with other proteins or isoforms. This meticulous approach ensures the highest level of specificity for your critical experiments.

Q: Which established scientific applications are validated for anti-Erythropoietin antibodies, and what are the key performance indicators for each?

A: Creative Biolabs' EPO antibodies are extensively validated for a range of common applications, including Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and ELISA. Our comprehensive data sheets provide specific protocols and recommended dilutions for optimal performance in each validated application. We continuously expand our validation efforts to support diverse research needs.

Q: From a scientific and technical standpoint, how do the performance characteristics of these anti-Erythropoietin antibodies compare to other commercially available reagents, particularly concerning sensitivity, signal-to-noise ratio, and batch consistency?

A: Creative Biolabs prides itself on delivering superior quality. Our EPO antibodies are distinguished by their high specificity, exceptional sensitivity, and consistent batch-to-batch performance, often outperforming other commercially available options in head-to-head comparisons. Our rigorous validation process and dedicated technical support ensure that you receive a product that truly elevates your research outcomes. Many of our clients report cleaner blots, brighter stains, and more reliable quantitative data compared to previous antibodies used.

Access the Creative Biolabs Edge – Request Your Quote Now

REFERENCES

Suresh, Sukanya et al. “The Many Facets of Erythropoietin Physiologic and Metabolic Response.” Frontiers in physiology vol. 10 1534. 17 Jan. 2020, DOI:10.3389/fphys.2019.01534. Distributed under Open Access license CC BY 4.0, without modification.